中文名称 | 法瑞西单抗 |
---|---|
英文名称 | Anti-Human VEGFAxANGPT2 (Faricimab; RG7716) |
CAS号 | 1607793-29-2 |
储存条件 | store at -20°C |
Faricimab is a pioneering humanized bispecific antibody that targets both VEGF-A and Ang-2, offering a dual inhibition approach for retinal diseases like DME and nAMD. By inhibiting VEGF-A, it reduces endothelial cell proliferation and vascular permeability, while blocking Ang-2 is believed to enhance vascular stability and counteract VEGF-A effects. Faricimab has demonstrated a significant reduction in annual injections compared to other anti-VEGF treatments, with a comparable efficacy and safety profile, positioning it as a valuable treatment option for patients with retinal diseases.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft